Why Partner With Us?
As an established regional specialty partner, we offer US pharmaceutical innovators a fully localized, turn-key commercialization ecosystem. We bypass public healthcare system delays and price controls by targeting the booming private, cash-pay aesthetics sector, mobilizing premium medical networks, and managing localized cold-chain logistics directly to point-of-sale.
Private Clinic Detail Network
We detail directly to the region's elite private ophthalmology, oculoplastic, and premium dermatology clinics, driving high-value peer-to-peer adoption.
Premium Retail Penetration
We secure preferred product placement across high-income private pharmacy networks and specialized aesthetic distribution outlets.
Sovereign Regulatory Sponsorship
We act as your local Marketing Authorization Holder, navigating ANVISA, COFEPRIS, and regional agencies on optimized private pathways.
Latin America Is a Strong Growth Opportunity at the Intersection of Aesthetics and Ophthalmology
Latin America combines strong aesthetic demand, expanding private healthcare capacity, and growing interest in minimally invasive treatments. Unlike many therapeutic categories, aesthetic procedures are primarily cash-pay, making adoption less dependent on reimbursement and more dependent on physician awareness, patient demand, and perceived value.
ISAPS reported 34.9 million aesthetic procedures performed by plastic surgeons worldwide in 2023, underscoring the scale of patient demand behind periocular and facial-aesthetics adoption.
Annual Aesthetic Procedures By Launch Market (ISAPS 2023)
Source-backed procedure counts show why Mexico and Colombia work as a concentrated proof-of-concept, while Brazil is the logical next expansion market. Venezuela remains a selective watchlist opportunity, but is not included in this chart until comparable published procedure data is available.
Mexico and Colombia Provide a Concentrated Launch Base
Mexico and Colombia offer an attractive first-stage launch base because they combine meaningful aesthetic procedure volume with relevant ophthalmology infrastructure. That combination is especially important for a product positioned at the intersection of periocular aesthetics and ophthalmic care.
Mexico
Launch MarketISAPS estimates approximately 1.7 million aesthetic procedures annually in Mexico, including more than 782,000 non-surgical procedures, nearly 588,000 injectable procedures, and more than 83,000 eyelid surgeries.
Colombia
Focused Launch MarketISAPS estimates approximately 447,000 aesthetic procedures annually in Colombia, including more than 176,000 non-surgical procedures, nearly 126,000 injectable procedures, and approximately 25,000 eyelid surgeries.
Combined Opportunity Snapshot
Together, Mexico and Colombia represent approximately 2.16 million annual aesthetic procedures, more than 958,000 non-surgical aesthetic procedures, more than 713,000 injectable procedures, and more than 108,000 eyelid surgeries. This creates a commercially relevant foundation for a staged launch strategy focused on physician education, periocular aesthetics, and category creation.
Brazil as the Logical Next Market
Beyond the initial Mexico and Colombia focus, Brazil materially expands the regional opportunity. With more than 3 million annual aesthetic procedures, it is a logical next market once early commercial and operational milestones are achieved.
Venezuela as a Selective High-Upside Watchlist
Venezuela appears commercially relevant again in specific private-pay pockets, especially where premium pharmacy retail, dollar-linked spending, and urban specialist care are re-emerging. But we should frame it as a selective expansion market rather than a first-wave launch because sanctions, FX volatility, import friction, and infrastructure reliability can still materially affect execution.
Conservative Base Case, With Directional Expanded Upside
Directional Upside OnlyThe current base estimate remains conservative because it uses published acquired ptosis prevalence data. The broader aesthetic opportunity can be significantly larger, but that upside should be framed directionally rather than as published epidemiology.
Estimated extended opportunity includes consumers seeking improvement in tired-eye appearance, periocular aging, post-Botox lid drop, and other aesthetic eyelid concerns. These figures should be presented as directional estimates generated from market analogs and AI-assisted modeling, not as published epidemiological studies.
Optimizing the Partnership Framework
Aesthetics out-licensing requires substantial distributor marketing investment to build brand awareness. To establish a sustainable business case, we propose a de-risked structure that shifts focus from high fixed costs to flexible, performance-driven incentives.
Proposed Value-Chain Allocation
Model Comparison Select
Licensor Transfer Price (35%)
A standard fixed transfer price of 35% NSP ensures immediate margins for the US partner, but limits regional volume-scaling capabilities.
Commitment To Marketing (25%)
We commit 25% of net sales to doctor masterclasses, local symposia, and visual consumer digital outreach.
Channel Management (40%)
Covers local specialized sales force deployment, cold-chain distribution logistics, and private pharmacy stocking margins.
Why We Are the Right LATAM Partner
We combine medical, operational, and commercial expertise under one structure. That matters because success in LATAM depends not only on distribution, but also on physician education, periocular-aesthetics credibility, regulatory execution, and disciplined market creation in private-pay settings.
Clinical and Category Expertise
Led by a U.S.-licensed, board-certified ophthalmologist with direct exposure to both U.S. clinical standards and Latin American healthcare realities.
This gives the program physician-facing credibility across ophthalmology, oculoplastics, and periocular aesthetics while supporting the education required to build a new prescription-led category.
Regulatory and Operational Execution
Leadership experience across medical affairs, clinical development, pharmacovigilance, regulatory affairs, and specialty pharmaceutical commercialization supports country-by-country launch planning.
That includes importation pathways, health-authority coordination, compliance requirements, distributor models, and launch-readiness execution.
Brand Development and Market Creation
We bring healthcare-focused brand strategy, physician education planning, audience intelligence, and consumer-facing communication needed to position Upneeq at the intersection of ophthalmology and aesthetics.
This is especially relevant in LATAM, where market adoption in private-pay categories depends on both doctor conviction and patient-perceived value.
Our Capabilities vs. Standard Distributors
3-Year Financial, FTE and Geo-Targeting Modeler
Simulate our commercialization plan. Adjust our target field deployment, clinic coverage goals, and product pricing to see our projected financial commitment to your brand.
Plan Core Variables
Field Force and Detailing Benchmarks
Our Proposed 3-Year Revenue and Promotional Allocation Model
Our Localized Geographic Targets and Patient Segmentation Plan
Affluent Micro-Target Hotspots
Loading target micro-geographies...
Target Patient Segments
High-net-worth ocular aesthetic seekers, premium presbyopic professionals, beauty-conscious patients, and luxury ocular wellness buyers.
Our Commercialization Channels
Direct doctor clinic dispensing, exclusive launch gala symposiums, and localized private-pay e-commerce patient support systems.
Distributor Pitch Deck and Term Sheet Architect
Formulate distributor-led strategic terms, mutual ROI structures, and launch defenses. Fill in our operational metrics and configure your API options to instantly generate a custom pitch proposal for the US IP Owner.
AI Access Setup
This site works in two public modes. On GitHub Pages, visitors can paste their own Gemini API key for browser-only AI requests. On a secure serverless deployment using the included api/generate.js backend, visitors can use AI features without exposing a key in the browser.
Pitch Customizer Variables
Our Specialized Capabilities (1 - 10)
Distributor Intelligence and Pitch Hub
Commercial Proposal Console
This workspace allows us to generate highly compelling, distributor-led licensing proposals and deal memos to share directly with the US patent owner.
- - Adjust capabilities on the left to show how our strengths visual map on the assessment chart.
- - Tap "Generate Capability Pitch" to construct a compelling partner argument highlighting our direct-to-clinic coverage.
- - Tap "Generate Term Sheet" to draft a financial split structure showing risk-sharing and minimum commitments.
Ptosis Launch Timeline and Regulatory Snapshot
A simplified partner-facing view focused on acquired ptosis only. Use it to discuss expected time to launch, reliance posture, budget range, and practical packaging considerations by market.
Partner Inputs
This version stays locked to acquired ptosis / eye-lift drops.
Illustrative Critical Path
A partner-friendly view of the likely filing-to-launch sequence.
Reliance and Evidence Notes
These points help frame what the local team usually needs from the originator dossier.
Local Regulatory Clearance and Price Freedom Blueprint
We handle the heavy lifting. Project your specialized product clearance timelines, private-pay pricing flexibility, and risk-mitigated regulatory pathways to show the US partner.
Submission Parameters
Consolidated Private Regulatory Clearance Blueprint
Select target parameters on the left and trigger the blueprint generator to receive our customized regulatory clearance, private pricing freedom schedules, and rapid-entry guidelines.